Group 1 - The former president of the company, Guan Yi, has resigned from the position of general manager due to personal reasons but will continue to serve as a director and hold relevant positions in the company's subsidiaries [2] - The company has experienced significant growth in revenue and net profit from 2021 to 2023, achieving double-digit year-on-year growth for three consecutive years [2] - However, the company has projected a net loss of approximately 240 million to 380 million yuan for the fiscal year 2025, representing a decline of 177.23% to 148.78% compared to the previous year [2] Group 2 - The company plans to enhance its management team by appointing experienced and influential professionals to operate in specialized lines [3] - There will be a continued investment in the health sector, leveraging the "Little Sunflower" brand to establish an "online-first + all-channel coverage" operational system [3] - The new management team members possess extensive industry experience and are well-aligned with the company's culture and operational model, which is expected to facilitate the implementation of the company's strategy and promote healthy and stable development [3]

证券日报网2月8日讯 ，葵花药业在接受调研者提问时表示，医药大健康领域是公司未来健康生态布局 中的核心重点之一。处方医药板块、OTC医药板块、大健康板块，三大板块共同发力，推动公司战略有 效落地。公司将分别配置资深、专业、有行业影响力的管理人员分线操作。未来，公司将持续加大大健 康领域的资源投入，依托"小葵花"品牌优势，构建"线上为主+全渠道覆盖"的运营体系，以专业化营销 团队为核心，强力打造。 （编辑 王雪儿） ...

南财智讯2月8日电，葵花药业在投资者关系活动中表示，医药大健康领域是公司未来健康生态布局中的 核心重点之一，公司将持续加大大健康领域的资源投入，依托"小葵花"品牌优势，构建"线上为主+全渠 道覆盖"的运营体系，以专业化营销团队为核心，强力打造。 ...